Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Travera Inc
Eastern Cooperative Oncology Group
University of Southern California
Masonic Cancer Center, University of Minnesota
Northwestern University